CelLBxHealth plc (CLBX) AGM Results: All Resolutions Passed Except Withdrawn Director Reappointment Following P M Collins' Exit

CelLBxHealth AGM on 14 July 2026: All Resolutions Passed Except Withdrawn Resolution 4

CelLBxHealth plc held its Annual General Meeting on 14 July 2026, where shareholders voted on several standard governance and management resolutions. The company confirmed that all resolutions were passed except Resolution 4, which was withdrawn prior to voting. This indicates shareholder support for the company’s governance plans for the upcoming year, consistent with typical AIM-listed company procedures.

Resolution 4 aimed to re-appoint Mr P M Collins as a Director but was withdrawn following his exit from the business shortly before the AGM. Shareholders were therefore not required to vote on this matter. Full voting results for the other resolutions are accessible via the Investor Relations section on CelLBxHealth’s website.

Director P M Collins Leaves CelLBxHealth on 6 July 2026 Ahead of AGM

The company announced that Mr P M Collins departed on 6 July 2026, eight days before the AGM. His departure led to the withdrawal of Resolution 4, originally intended for his re-appointment. The announcement did not disclose reasons for his exit, nor any financial or transition arrangements. No information was provided regarding his prior role or whether a replacement is planned. Investors may seek further updates on board changes as the company communicates in the future. The immediate impact on share price remains unclear.

Parsortix Platform: Core Technology Driving CelLBxHealth’s CTC Intelligence

CelLBxHealth’s operations centre on its patented Parsortix platform, designed to capture circulating tumour cells (CTCs) from blood samples. This non-invasive technology offers an alternative to traditional tissue biopsies for oncology research and clinical use. The platform integrates with laboratory instruments to enable downstream analyses such as whole-cell imaging, proteomics, and genomics. Its versatility across these modalities positions Parsortix as a valuable tool within life sciences and oncology diagnostics.

CTCs, shed by solid tumours into the bloodstream, provide critical insights into cancer biology, treatment response, and disease progression. The ability to capture these cells non-invasively aligns with the growing demand for precision medicine and personalised cancer therapies. CelLBxHealth’s focus on CTC intelligence places it in a rapidly expanding oncology diagnostics and liquid biopsy market, supported by patent protection that offers competitive advantages.

Three Revenue Streams Form CelLBxHealth’s Commercial Strategy in Research and Clinical Markets

The company’s commercial model is built on three revenue streams: Product Sales, Laboratory Services, and Lab Developed Tests (LDTs). Product Sales include the Parsortix hardware and consumables, distributed via partnerships with contract research organisations (CROs) and clinical labs, generating recurring revenues from consumable use.

Laboratory Services cover clinical trial support and assay development, conducted in a Good Clinical Laboratory Practice (GCLP)-compliant UK facility, underscoring the company’s commitment to regulatory standards. The third stream, LDTs, is pursued through strategic partnerships and internal development. Together, these streams aim to diversify income across early research to clinical oncology, though specific revenue figures were not disclosed.

UK and US Operations Position CelLBxHealth in Key Oncology Markets

Headquartered in Guildford, UK, with operations in Plymouth Meeting, Pennsylvania, US, CelLBxHealth strategically covers two major oncology markets. The US location benefits from proximity to a robust pharmaceutical and life sciences cluster in the Philadelphia region, a hub for oncology drug development.

The UK base includes the GCLP-compliant laboratory supporting Laboratory Services and benefits from access to the National Health Service’s oncology infrastructure and academic research. CelLBxHealth’s shares trade on AIM, operated by the London Stock Exchange, a popular platform for growth-stage UK life sciences firms. Cavendish serves as NOMAD and broker, with Walbrook PR managing investor and media relations. Executive Chairman Jan Groen is the lead contact for investor inquiries.

AGM Voting Results Available on CelLBxHealth Investor Relations Website

Following the AGM, CelLBxHealth published detailed voting results for all resolutions on its Investor Relations website. Stakeholders can review vote counts for, against, and abstentions in the general meeting documentation section. This transparency aligns with AIM governance standards and allows shareholders who did not attend or vote to assess shareholder support levels. The company did not include detailed voting tables in its announcement, directing investors to its website for full data.

Board Governance Led by Executive Chairman Jan Groen

Jan Groen serves as Executive Chairman of CelLBxHealth and is the primary contact for investor relations via Walbrook PR. His role combines executive leadership with board oversight, highlighting the company’s focus on strong governance and investor engagement.

With Mr Collins’ departure, investors may closely watch any board restructuring or new appointments. The announcement did not specify current board size or plans to fill vacancies. AIM corporate governance guidelines emphasize balanced boards, making future updates on board composition relevant for shareholders evaluating governance standards.

Oncology Diagnostics Growth and Increasing Importance of Liquid Biopsy Technologies

CelLBxHealth operates amid strong scientific progress and rising clinical adoption of liquid biopsy methods, which analyze tumour-derived materials like circulating tumour cells, cell-free DNA, and exosomes from blood samples. These minimally invasive techniques are gaining traction for disease monitoring, treatment evaluation, and early cancer detection.

The global oncology diagnostics market is expanding due to higher cancer incidence, precision medicine investments, and targeted therapy pipelines requiring companion diagnostics. The Parsortix platform’s capacity to isolate intact CTCs for multi-modal analysis addresses a specialized niche within this growing market. The company’s three-pronged commercial strategy aims to capture value across oncology research and clinical pathways, though no revenue or profitability data were disclosed in the AGM announcement.

Risks Facing CelLBxHealth as a Development-Stage AIM Life Sciences Company

As a development-stage AIM-listed company in oncology diagnostics, CelLBxHealth faces risks related to technology adoption, regulatory approvals, and leadership changes. Successful commercialisation of the Parsortix platform depends on uptake by CROs, clinical labs, and pharmaceutical developers, which can be slow due to integration and validation requirements.

The recent board director departure may introduce strategic uncertainty. Additionally, Lab Developed Tests face regulatory and clinical validation challenges in UK and US markets. Investors should consider these factors when evaluating the company’s risk profile.

Implications of AGM Outcomes for CelLBxHealth’s Corporate Direction

The approval of all substantive resolutions at the 14 July 2026 AGM reflects shareholder support for CelLBxHealth’s current governance and strategic direction. The withdrawal of Resolution 4 was procedural following Mr Collins’ exit and does not indicate shareholder dissatisfaction.

Looking forward, investors will focus on execution of the three-stream commercial strategy, Parsortix platform adoption by partners, developments in Lab Developed Tests, and any board appointments post-Collins. Updates on clinical partnerships and financial performance will also be closely watched. No financial guidance or milestones were provided in the AGM announcement.